Early Aspirin Discontinuation Postacute Coronary Syndrome: A New Approach to Postmyocardial Infarction Management

Area of Science:

• Cardiology
• Pharmacology

Background:

• Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor for 12 months is standard for acute coronary syndrome (ACS) post-percutaneous coronary intervention (PCI).
• DAPT reduces thrombotic events but increases major bleeding risk.

Purpose of the Study:

• To review literature on discontinuing aspirin to evaluate P2Y12 monotherapy's efficacy in reducing bleeding without increasing ischemic events.
• To determine the optimal timing for aspirin discontinuation post-PCI.

Main Methods:

• Literature review synthesizing recent trials and analyses on DAPT de-escalation strategies.
• Evaluation of studies comparing aspirin discontinuation versus continued DAPT.

Main Results:

• Aspirin discontinuation generally reduced bleeding events compared to DAPT.
• Cardiovascular outcomes were not significantly increased in selected ACS patients.
• Evidence is strongest for lower-risk ACS patients; myocardial infarction-specific data is limited.

Conclusions:

• Discontinuing aspirin at 1 or 3 months post-PCI is a promising strategy to reduce bleeding risk.
• Individualized patient risk assessment for bleeding and ischemia is essential for optimal timing.